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The IGF system plays vital roles in neuronal develop-
ment, metabolism, regeneration and survival. It consists of
IGF-I, IGF-II, insulin, IGF-I-receptor, and those of IGF-
II and insulin as well as IGF-binding proteins. In the last
decades it has become clear that perturbations of the IGF
system play important roles in the pathogenesis of diabetic
neurological complications. In the peripheral nervous sys-
temIGF-I,insulin,andC-peptideparticularlyintype1dia-
betesparticipateinthedevelopmentofaxonaldegenerative
changes and contributes to impaired regenerative capaci-
ties. These abnormalities of the IGF system appear to be
less pronounced in type 2 diabetes, which may in part ac-
count for the relatively milder neurological complications
in this type of diabetes. The members of the IGF system
also provide anti-apoptotic effects on both peripheral and
central nervous system neurons. Furthermore, both insulin
and C-peptide and probably IGF-I possess gene regulatory
capacities on myelin constituents and axonal cytoskeletal
proteins. Therefore, replenishment of various members of
the IGF system provides a reasonable rational for preven-
tion and treatment of diabetic neurological complications.
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INTRODUCTION
Deﬁnition of the Insulin-Like Growth Factor
(IGF) System
The IGF system consists of IGF-I, IGF-II, insulin, insulin-
like growth factor receptors (IGF-IRs), insulin receptor (IR),
and IGF-binding proteins (IGFBPs) (Le Roith, 1999). IGF-I
and IGF-II are single-chain polypeptides similar to that of
proinsulin and their amino acid sequences share extensive ho-
mologies with insulin (Blundell et al., 1983; Rinderknecht and
Humbel, 1978). Both IGF-I and IGF-II signal predominantly
via the IGF-IR, whereas insulin acts primararily through the
IR. IGF-IR and IR are tyrosine kinase receptors characterized
byα2β2heterotetramersthatareheldbydisulﬁdebonds(Ullrich
and Schlessinger, 1990). The β subunit of IGF-IR shares a
high homology (84%) with that of IR, whereas the cysteine-
rich pockets of the α subunit of IGF-IR shows low homol-
ogy (48%) with that of IR (Ullrich et al., 1986). IGF-I and
insulin bind weakly to each other’s receptors, with a 1000-
fold lower afﬁnity than that for the cognate receptor (Kjeldsen
et al., 1991). IGF-IIR is a receptor that differs from IGF-IR
and IR, as it has a single transmembrane protein bearing bind-
ing sites for mannose-6-phosphate–containing residues (Kiess
et al., 1994), while IGF-IR and IR are tyrosine kinase receptors
(Figure 1).
Inspiteoftheirstructuralsimilarities,IGF-IRandIRmediate
different effects: mainly metabolic effects for IR and predomi-
nantly growth effects for IGF-IR. The mechanisms underlying
the speciﬁcities of the IGF-IR and IR signaling are not totally
clear. Several mechanisms are probably of importance, such as
differences in tissue distribution, modulation of ligand bind-
ing by local environments, such as IGFBPs, and differences in
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FIGURE 1
Summary of IGF system. The IGF system consists of IGF-I, IGF-II, insulin, insulin-like growth factor receptors (IGF-IR and
IGF-IIR), insulin receptor (IR), and IGF-binding proteins (IGFBPs). In addition to these are the insulinomimetic C-peptide.
IGF-I and IGF-II are single-chain polypeptides and bind to IGF-IR with high afﬁnity, whereas insulin acts primarily through the
IR. IGF-IIR is a single transmembrane peptide bearing binding sites for mannose-6-phosphate, its signaling and function being
unclear. IGF-I and IGF-II are interactive with IGFBPs, whereas insulin does not bind to IGFBPs. Although IGF-IR and IR utilize
similar signaling pathways, IGF-IR and IR mediate different effects: mainly metabolic effects for IR and predominantly growth
effects for IGF-IR. In addition, recent studies have shown that both IGF-IR and IR mediate antiapoptotic effects. The weak
binding of IGF-I/IGF-II to IR and insulin to IGF-IR are indicated with dotted lines. C-peptide shows insulin-like effects, although
its receptor binding is not clear. It appears to regulate the expression of both IGF-I, IGF-II, IGF-IR, and IR possibly,
via NF-κB.
downstream substrates (Blakesley et al., 1996). To deﬁne func-
tional speciﬁcity, mutations of the various domains of IGF-IR
and IR have been performed. For IGF-IR, the tyrosine cluster
1131, 1135, and 1136 (Gronborg et al., 1993; Li et al., 1994)
and tyrosine 950 (Miura et al., 1995a) are crucial for both mi-
togenic and transformation activities, but not for antiapoptotic
activity. Substitution of tyrosine 1251 with phenylalanine re-
sults in a loss of the antiapoptotic activity (O’Connor et al.,
1997) and a reduced transformation activity, but it does not af-
fect mitogenicity (Miura et al., 1995b). These data indicate that
domains required for inhibition of apoptosis are distinct from
those essential for both transformation and mitogenicity. With
respect to the IR, mutation experiments have established rela-
tionshipsbetweenphosphorylationofspeciﬁcreceptorsitesand
activation of the receptor kinase activity (Avruch et al., 1990;
Flores-Riverosetal.,1989;TavareandDenton,1988;Tornqvist
et al., 1987; White et al., 1988). The Tyr-1150 domain, includ-
ingthreetyrosineresiduesatpositions1146,1150,and1151,is
crucial for IR tyrosine kinase activity (Hashimoto et al., 1992).
MutationattheATPbindingsites(Lys-1018orLys-1030inthe
β subunitofIR)leadstolossofinsulin-stimulatedkinaseactiv-
ity (Chou et al., 1987; Ebina et al., 1987). In contrast, the phos-
phorylationoftyrosines1316and1322inthecarboxyl-terminal
region do not inﬂuence the receptor kinase activity (MaegawaIGF AND NEUROLOGICAL COMPLICATIONS 237
et al., 1988; Myers et al., 1991; Takata et al., 1991). These
results suggest that speciﬁcally located tyrosine domains of the
IRand IGF-IR may be required for speciﬁc ligand-induced cel-
lular functions.
The IGFs are associated with high-molecular-weight carrier
proteins, IGFBPs, present in the circulation and brain (Baxter,
2000). Currently, six different IGFBPs have been identiﬁed.
They share a cysteine-rich region but differ substantially in
other regions (Baxter, 1994; Katz et al., 1995). The interac-
tion of IGFs with their receptor is controlled by IGFBPs. Most
of the IGFs in the circulation are bound to IGFBPs, because
the afﬁnity of IGFs for the IGFBPs is greater than that for the
IGF receptors. When the afﬁnity of IGFBPs for IGFs is re-
duced, the IGFs are released to interact with the IGF receptors
(Blakesley et al., 1996). Therefore, IGFBPs act as partitioning
agentscontrollingtheamountofIGFthatisavailableforrecep-
tor association. Three factors have been found to be important
forregulationofIGFBPafﬁnity:(a)associationwithextracellu-
lar matrix proteins reduces IGFBP afﬁnity (Jones et al., 1993);
(b) proteolytic cleavage of IGFBP reduces greatly the afﬁnity
for IGFs (Clemmons et al., 1998); and (c) phosphorylation of
serine residues on IGFBP-1 results in 6- to 7-fold enhancement
of its afﬁnity for IGF-I (Jones et al., 1991). In the rat, IGFBP-3
is the principal carrier protein for IGFs in the circulation (Katz
et al., 1995). Under physiological conditions, IGFBP-2, -3, -4,
-5, and -6 are expressed in the central nervous system (CNS),
IGFBP-2 being the predominant IGFBP (Walter et al., 1999).
Diabetes affects the levels of IGFBPs. IGFBP-1 is increased
in streptozotocin (STZ)-induced diabetic rats and patients
(DeLaPuenteetal.,2000;Landauetal.,1995;LuoandMurphy,
1991; Park et al., 1998; Price et al., 1997; Rodgers et al., 1995),
whereas IGFBP-3 is decreased (Cinaz et al., 1996; Graubert
et al., 1991). The expression of IGFBP genes is regulated by
insulin: insulin inhibits IGFBP-1 and stimulates IGFBP-3 gene
transcription (Graubert et al., 1991; Katz et al., 1998).
In summary, the IGF system is a complicated system con-
sisting of ligands, receptors, and interacting binding proteins.
The components of this system interact with each other in a
complicated mode. The ligands of the IGF system may interact
withotherreceptorsbesidestheirown,forexample,IGF-Ibinds
to the IR and insulin binds to IGF-IR, however, with low afﬁni-
ties. Therefore, IGF-I signaling is not an isolated phenomenon.
It is modulated by the presence of IGFBPs, and probably by in-
sulin and maybe by C-peptide. These interactive relationships
account for the intricate function of the IGF system. As men-
tionedearlier,theIGFsystemconsistsofIGF-I,IGF-II,IGF-IR,
IGF-IIR, IGFBPs, and IR. To this series of associated trophic
factors, we propose to add the proinsulin C-peptide as an in-
teractive member of the system for reasons that will become
clear.
Function of the IGF System
TheIGFsystemplaysavitalroleinmediatinggrowth,devel-
opment, metabolism, and survival of many tissues and organs.
Inneuronaltissues,theIGFsystemsupportsthesurvivalofneu-
rons (Ang et al., 1992; Zackenfels et al., 1995; Zackenfels and
Rohrer, 1993; Zheng et al., 2002) and Schwann cells (Cheng
andFeldman,1997;Syroidetal.,1999),regulatesneuronaldif-
ferentiation(ArsenijevicandWeiss,1998;Brookeretal.,2000;
Feldmanetal.,1997;Morrioneetal.,2000;Ochoaetal.,1997),
enhances regeneration in cultured adult rat sensory neurons
(Fernyhough et al., 1993), stimulates neurite outgrowth (Kim
et al., 1997; Rind and von Bartheld, 2002; Wang et al., 1992;
Zhang et al., 2001), enhances oligodendrocyte development
(D’Ercole et al., 1996; Dubois-Dalcq and Murray, 2000; Jiang
et al., 2001; McMorris and McKinnon, 1996), promotes myeli-
nation of the nervous system (Cheng et al., 1999; Copelman
et al., 2000; Hetts et al., 1997; Mozell and McMorris, 1991;
Russell et al., 2000; Ye et al., 1995; Zackenfels et al., 1995),
rescues neuronal loss following cerebral hypoxic-ischemic in-
jury (Gluckman et al., 1992; Guan et al., 1993; Williams et al.,
1995), and protects against neuronal apoptosis (Zawada et al.,
1998; Zhang et al., 2002). IGF-I has been used in the treatment
of several disorders, including growth deﬁciency, osteoporosis,
catabolic disorders, diabetes, and neurodegenerative disorders
(Doreetal.,1997).TheratheruniquepropensityofIGF-Itoact
on a variety of neuronal cells might provide a general means of
reducing or slowing down neuronal losses that occur following
various brain insults.
IGF-I regulates calcium ion channel currents and neuronal
excitability (Blair and Marshall, 1997; Hall et al., 1995; Ristic
et al., 1998; Selinfreund and Blair, 1994). The rapid action
of IGF-I on the voltage sensitivity of L-type calcium chan-
nel indicates that IGF-I, in addition to function as a mitogen
with long-term effects, also acts as a rapid neuromodulator
(Bence-Hanulec et al., 2000). IGF-I rapidly promotes phos-
phorylationoftheα1subunitofthecalciumL-channel(Bence-
Hanulecetal.,2000)andactivatesthephosphatidylinositol(PI)
3-kinase/Akt pathway (Blair et al., 1999), which may promote
the survival of cerebellar granule neurons. Besides calcium
channels, IGF-I up-regulates potassium channels through PI
3-kinase, PDK1, and SGK1 pathways to exert the proliferative
action of the growth factor (Gamper et al., 2002) and it may
modulate sodium channel expression (Craner et al., 2002).
Recent studies show that the IGF system plays antiapoptotic
effects in various types of cells, including hematopoietic cells
(Kelley et al., 1998; Zumkeller, 2002), osteoblasts (Hill et al.,
1997; Kawakami et al., 1998; Tumber et al., 2000), ﬁbroblasts
(Buckley et al., 2002; Valentinis et al., 1999), melanoma cells
(Kanter-Lewensohn et al., 2000), myoblasts (Foulstone et al.,
2001; Hong et al., 2001), mouse embryonic ﬁbroblast NIH3T3238 A. A. F. SIMA ET AL.
cells (Sell et al., 1995), NWTb3 cells, NIH3T3 cells expressing
the normal human IGF-IR (Heron-Milhavet et al., 2001), and
epithelialcells(Mooreheadetal.,2001;Wilkinsetal.,2002).In
neuronal cells, it promotes neuronal survival following ultravi-
olet (UV) irradiation (Kulik et al., 1997) and serum deprivation
in PC12 cells (Parrizas et al., 1997b). It inhibits apoptosis of
cerebellargranuleneuronsinducedbylowpotassium(D’Mello
et al., 1997; Galli et al., 1995), and protects against apoptosis
ofdoralrootganglia(DRG)andSchwanncellsexposedtohigh
glucose(Delaneyetal.,2001;Russelletal.,1999;Vincentetal.,
2002) and neuroblastoma SH-SY5Y cells exposed to high con-
centration of mannitol or glucose (Cheng and Feldman, 1998;
MatthewsandFeldman,1996;Singletonetal.,1996;vanGolen
and Feldman, 2000; Vestling et al., 2001; Vincent et al., 2002;
Zhang et al., 2001) or to 3-morpholinosydnonimine (SIN-1), a
peroxynitrite donor (Saeki et al., 2002). On the other hand,
decreased IGF-I gene expression is found in Purkinje cells
undergoingapoptosis(Zhangetal.,1997)andinhibitionofIGF-
I activity appears to contribute to premature apoptosis of cere-
bellargranuleneuronsintheweavermutantmice(Zhongetal.,
2002). IGF-I and IGF-II (3 to 100 ng/mL) each prevents glu-
cosedeprivation–inducedneuronaldamageinadose-dependent
manner in rat hippocampal and septal neuronal cell cultures,
whereas insulin exhibits a protective effect at high concentra-
tions(greaterthan1µg/mL)andepithelialgrowthfactor(EGF)
does not show any protective effect at all (Cheng and Mattson,
1992). This latter study is in accordance with the results of
other investigators, who show that the IGF-I, but not EGF
and ﬁbroblast growth factor (FGF), protects against c-Myc–
inducedapoptosisinRat-1ﬁbroblastsviatheactivationofIGF-
IR (Harrington et al., 1994), and that the IGF-I, but not acidic
FGF (aFGF), basic FGF (bFGF), nerve growth factor (NGF),
and platelet-derived growth factor (PDGF), rescues neuroblas-
toma SH-SY5Y apoptosis induced by hyperosmolarity (van
Golen and Feldman, 2000). Therefore, it is well documented
that IGF-I exerts antiapoptotic effects via IGF-IR signaling.
TheIGF-IRsignalingmayutilizemultiplepathwaysinacell
type–speciﬁc manner to exert its antiapoptotic activity: the PI
3-kinase/Akt pathway in Rat-1 cells, promyeloid cells, PC 12
cells, and DRG neurons (Dudek et al., 1997; Liu et al., 1997;
Parrizas et al., 1997b); the MAP (mitogen-activated protein)
kinase pathway in PC 12 cells (Cano et al., 1996); the Crk-II–
enhanced Ras-dependent but Raf-1/MAP kinase–independent
pathway in human embryonic kidney 293 cells (Parrizas
et al., 1997a); the stress-activated p38 MAP kinase and c-Jun
N-terminal kinase (JNK) pathway in neuroblastoma cells
(Cheng and Feldman, 1998; Okubo et al., 1998; Zhang et al.,
2001); p38 MAP kinase pathway in NWTb3 cells (Heron-
Milhavet et al., 2001); up-regulation of Bcl-xl and activation
of PI 3-kinase in Baf-3 cells (Leverrier et al., 1999); and
PI 3-kinase in mouse neocortical neuronal cell cultures (Ryu
et al., 1999). Among the multiple signaling pathways that
are involved in the IGF-IR–mediated antiapoptotic effect, PI
3-kinase/Akt pathway plays a key role and MAP kinase path-
ways are implicated. As illustrated in Figure 2a, binding of
IGF-I/IGF-II to IGF-IR activates autophosphorylation of the
receptor and phosphorylation of several intracellular substrate
proteins (IRS family and Shc), and leads to activation of PI
3-kinase/Akt pathway and MAP kinase pathway (Figure 2).
TheactivatedAktinactivatesproapoptosisfactors,suchasBad,
p53,andcaspase-3(Baietal.,1999;Brunetetal.,1999;Kermer
et al., 2000; Yamaguchi et al., 2001); increases antiapoptosis
factors, such as Bcl2 and Bclx (Leverrier et al., 1999; Li et al.,
2001;Zhangetal.,2002);activatestranscriptionalfactors,such
as nuclear factor [NF]-κB (Heck et al., 1999; Li et al., 2001)
and cyclic AMP response element–binding protein (CREB)
(Pugazhenthi et al., 1999). It decreases forkhead transcription
factor (FKH) (Brownawell et al., 2001; Kops and Burgering,
2000), which reduces expression of FKH target genes, includ-
ing Fas ligand, and therefore decreases Fas-mediated apoptosis
(Vincent and Feldman, 2002). With respect to the MAP ki-
nase pathway, the activated extracellular signal–regulated ki-
nase (ERK) inactivates Bad (Bonni et al., 1999; Scheid et al.,
1999) and the p38 MAP kinase activates CREB (Bonni et al.,
1999;Pugazhenthietal.,1999).Overallactivationofthesepath-
ways results in antiapoptotic effects.
In contrast to IGF-IR, the IR-mitigated antiapoptotic effects
are not totally clear. As shown in Figure 2b, insulin inhibits
serumwithdrawalinducedChinesehamsterovarian(CHO)cell
apoptosis via a PI 3-kinase–dependent pathway (Lee-Kwon
et al., 1998) and a Raf-1–dependent pathway, which leads
to activation of NF-κB (Bertrand et al., 1998) and the NF-
κB–dependent survival genes encoding tumor necrosis factor
receptor–associatedfactor2(TRAF2)andmanganesesuperox-
idedismutase(Mn-SOD)(Bertrandetal.,1999).Insulinrescues
serum-deprivedimmortalizedbrownadipocytesfromapoptosis
through PI 3-kinase/Akt pathways (Navarro et al., 2000), pre-
vents cardiomyocytes from oxidative stress–induced apoptosis
through activation of PI 3-kinase/Akt (Aikawa et al., 2000),
and inhibits apoptosis of macrophage THP-1 cells, via a PI
3-kinase–dependent pathway (Iida et al., 2002). Data from our
laboratory show that insulin activates p38 kinase, inhibits JNK,
andpromotesnucleartranslocationofNF-κBinneuroblastoma
SH-SY5Y cells, indicating that these pathways are involved in
IR-mediated antiapoptotic effects (Zhang et al., 2002).
Furthermore, recent studies show that other components of
theIGFsystembesidesIGF-IR,includingIRandIGFBPs,play
antiapoptoticroles.Insulinexertsanantiapoptoticeffectinvar-
ious cell types, including external granular layer neurons in rat
cerebellar slice cultures (Tanaka et al., 1995), Rat-1 ﬁbroblastsIGF AND NEUROLOGICAL COMPLICATIONS 239
FIGURE 2
Summary of IGF-IR and IR pathways mediating antiapoptotic effects by IGFs. (A) IGF-IR signaling pathways. Binding of
IGF-I/IGF-II to IGF-IR activates autophosphorylation of the receptor and of several intracellular substrate proteins (IRS family
and Shc), leading to activation of PI 3-kinase/Akt pathway and MAP kinase pathway. The activated Akt inactivates proapoptosis
factors, such as Bad, p53, and caspase-3); increases antiapoptosis factors, such as Bcl2 and Bclx); and activates transcriptional
factors, such as nuclear factor (NF)-κB and cyclic AMP response element binding protein (CREB). It decreases forkhead
transcription factor (FKH), which reduces expression of FKH target genes, including Fas ligand and therefore decreases
Fas-mediated apoptosis. With respect to the MAP kinase pathway, the activated extracellular signal–regulated kinase (ERK)
inactivates Bad. The p38 MAP kinase activates CREB. Overall activation of these pathways results in antiapoptotic effects.
(B) IR pathways. The IR-mitigated antiapoptotic effects are not totally clear. Insulin inhibits apoptosis via a PI 3-kinase/Akt
pathway and a Raf-1–dependent pathway, each of wich leads to activation of NF-κB. The NF-κB–dependent survival genes
encoding tumor necrosis factor receptor–associated factor 2 (TRAF2) and manganese superoxide dismutase (Mn-SOD). Data
from our laboratory show that insulin activates p38 kinase, inhibits JNK, and promotes nuclear translocation of NF-κBi n
neuroblastoma SH-SY5Y cells (Zhang et al., 2002). All these pathways are involved in IR-mediated antiapoptotic effects.
(Continued)
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(Kummer et al., 1997), macrophages (Iida et al., 2002), serum-
deprivedimmortalizedbrownadipocytes(Navarroetal.,2000),
cardiomyocytes of neonatal rats (Aikawa et al., 2000), and cul-
tured rat adipocytes (Qian et al., 2001). In many studies, this
effect was observed at high concentrations of insulin. It was
therefore believed that the observed antiapoptotic function was
mediatedviaIGF-IRandnotbyIRitself.However,Lee-Kwong
et al. (1998), Bertrand et al. (1998), and Kummer et al. (1997)
independently reported that low doses of insulin rescue CHO
cellsCHOorRat-1ﬁbroblastsfromapoptosisinducedbyserum
starvation. These results indicate that IR indeed mediates an
antiapoptotic effect. We have shown that low doses of insulin
stimulateneuriteoutgrowth,enhancecellproliferation,andpro-
tect against high glucose–induced apoptosis of neuroblastoma
SH-SY5Y cells (Zhang et al., 2001, 2002). These data support
the notion that insulin plays an antiapoptotic function via its
own receptors. Furthermore, the combination of low doses of
C-peptide and insulin give rise to an additive effect on neurite
outgrowth, cell proliferation, and antiapoptosis in SH-SY5Y
cells (Zhang et al., 2001, 2002), indicating that the proinsulin
C-peptide may play an active role in the interactions of the IGF
system.
IGFs are implicated in neurodegenerative disorders. Serum
levels of insulin and IGFs and their binding proteins are per-
turbed in various human neurodegenerative disorders, such as
Alzheimer’s disease, amyotrophic lateral sclerosis, cerebellar
ataxia,ataxia-telangiectasia(AT),andCharcot-Marie-Tooth1A
(CMT-1A)disease(Busiguinaetal.,2000).Similarly,serumin-
sulinandIGF-Ilevelsaredecreasedindiabeticpatients(Bereket
et al., 1996; Cinaz et al., 1996; Clauson et al., 1998; Fujihara
et al., 1996; Normann et al., 1994; Rieu and Binoux, 1985; Tan
and Baxter, 1986). Furthermore, neuronal apoptosis has been
demonstrated in both neurodegenerative disorders (Mattson,
2000; Mizuno et al., 1998; Tatton et al., 1997) and in exper-
imental type 1 diabetes (Li et al., 2002a). These results suggest
that similar mechanisms may be operable in a variety of neu-
rodegenerative disorder and CNS complications of diabetes.
However,moreworkisrequiredtoelucidatethepotentialpatho-
genetic roles of IGFs in neurodegenerative disorders, such as
Alzheimer’s disease and the CNS complication of diabetes.
IGFBPs also play a role in the regulation of apoptosis.
IGFBP-5 decreases apoptosis in human breast cancer cells
(Perksetal.,2000),whereasIGFBP-3increasesapoptosisinthe
samecells(Baxter,2001;Perksetal.,2000).Anotherantiapop-
totic factor that may be related to the IGF system is the IGF-I–
cleaving protease. It releases from the amino-terminal of IGF-I
molecule a tripeptide Gly-Pro-Glu (Guan et al., 1999), which
protects neuronal death in Huntington’s disease, Parkinson’s
disease, cerebral hypoxic-ischemic injury, and N-methyl-D-
aspartate (NMDA) toxicity (Alexi et al., 1999; Guan et al.,
2000; Sara et al., 1989; Sizonenko et al., 2001).
NEUROLOGICAL COMPLICATIONS
OF DIABETES
Diabetesisachronicmetabolicdisorderthatisreachingpan-
demic proportions. The two major forms are type 1 (or insulin-
dependent) and type 2 (non–insulin-dependent) diabetes mel-
litus. They both have in common hyperglycemia and are apt to
develop chronic complications such as nephropathy, neuropa-
thy, retinopathy, and encephalopathy and to predispose to car-
diovasculardisease.Althoughbothtypesofdiabetesdodevelop
chronic complications, they differ in their expression and pro-
gression,whichislikelyareﬂectionofdifferencesinunderlying
pathogenetic mechanisms. For a long time, it was believed, and
unfortunatelystillistosomeextent,thathyperglycemiawasthe
only culprit underlying the chronic complications of diabetes
and hence by deﬁnition they were the same in the two types ofIGF AND NEUROLOGICAL COMPLICATIONS 241
diabetes. In recent years, however, it has become increasingly
evident that factors such as insulin deﬁciency and associated
C-peptide deﬁciency, as well as progressive perturbations of
trophic factors in type 1 diabetes play important roles in the
pathophysiology in most of the chronic complications and may
be responsible for the usually more severe forms of compli-
cations in this type of diabetes (Kohner, 1987; Marshall and
Alberti, 1989; Mogensen, 1998; Sima et al., 1988; Sugimoto
et al., 2000a).
The IGF system has been implicated in the pathogenesis
of the chronic complications, such as the role of IGF-I in the
development of diabetic neuropathy (Ishii, 1995), cardiovascu-
lar disease in type 2 diabetes (Janssen and Lamberts, 2002),
and in diabetic angiopathy (Chiarelli et al., 2000; Janssen and
Lamberts, 2000). In this article, we will focus on the neuro-
logical complications and IGFs, their neurotrophic effects that
support nerve integrity and regeneration, and their protective
effects on neuronal survival (Zhuang et al., 1997).
PERIPHERAL NEUROPATHY
Diabetic neuropathies as a group are the most common
chroniccomplicationofdiabetesmellitus(Greeneetal.,1997),
but remain probably the least understood complication. The
prevalence of diabetic neuropathy varies from 10% within 1
year of diagnosis of diabetes to 50% in patients with diabetes
for more than 25 years (Dyck et al., 1993; Pirart, 1977;
Sima, 1997; Vinik et al., 1992). Diabetic neuropathies in-
clude several distinct syndromes, among which distal symmet-
ric polyneuropathy, often associated with diabetic autonomic
neuropathy, is the most common and is referred to as dia-
betic polyneuropathy (DPN). The different syndromes affect-
ing peripheral nerve can be separated into rapidly reversible
manifestations and chronic progressive syndromes. The lat-
ter can be divided into symmetric polyneuropathies and focal/
multifocal neuropathies (Sima, 1997; Sima et al., 1997c;
Thomas, 1997).
The mechanisms underlying DPN are multiple and appear
to involve several interrelated metabolic abnormalities conse-
quent to hyperglycemia and insulin and C-peptide deﬁciencies
(Greene et al., 1992, 1997; Sima, 1996; Sima and Sugimoto,
1999; Sima et al., 2001b; Sugimoto et al., 2000a, 2000c).
The results from the Diabetes Control and Complications
Trial (DCCT) support this notion. Intensive glycemic control
for 5 years reduced the incidence of clinical neuropathy by
60% in type 1 patients (The DCCT Research Group, 1993).
The fact that strict hyperglycemic control did not completely
preventdiabeticneuropathy(oranyoftheothercomplications),
suggests additional pathogenetic attributes such as genetic pre-
dispositions, insulin/C-peptide deﬁciencies, and perturbations
of trophic factors.
DPN shows a more severe clinical course in type 1 patients,
associated with more severe structural changes compared to
duration-matchedtype2patients(Dycketal.,1999;Simaetal.,
1988). Perturbations in the expression of insulin receptor and
that of other growth factors and their receptors, either does not
occuroraremildinatype2animalmodel(Piersonetal.,2002a).
We and others (Sima et al., 2000, 2001a; Yagihashi, 1995;
Yagihashi et al., 1994) have explored some of the differences
in DPN in type 1 versus type 2 animal models. Comparisons
oftwoisohyperglycemicmodelshavedemonstratedfunctional,
biochemical, molecular, and structural differences, which have
been ascribed to the presence/absence of insulin and/or the in-
sulinomimetic C-peptide (Sima et al., 2000, 2001b). Type 1
DPN is in both experimental models and patients character-
ized by severe axonal atrophy resulting in a dying-back–type
axonopathy with progressive nerve ﬁber loss. This latter phe-
nomenon is probably in part due to impaired nerve ﬁber regen-
eration. Furthermore, progressive nodal and paranodal changes
occur in type 1 but not in type 2 DPN. Type 2 DPN, on the
other hand, shows a milder axonal atrophy, mild axonal loss,
and normal regenerative capacity, but an increased frequency
of segmental demyelination (Sima et al., 1986, 1988, 1997c;
Sima and Sugimoto, 1999; Sugimoto et al., 2000a; Yagihashi,
1995; Yagihashi et al., 1994). It was recently shown that in-
sulintreatmentenhancestheexpressionofIGF-Iinsuralnerves
of diabetic patients (Grandis et al., 2001) and that C-peptide
corrects partially the decreased activity of IGFs in hippocam-
pus of type 1 diabetes (Li et al., 2002b), supporting the above
notion.
IGFs and DPN
Unlike NGF, IGFs exert their neurotrophic effects on most
peripheral nerve ﬁbers, be they sensory, motor, or autonomic.
The neurotrophic support by the IGF system was recognized in
the mid 1980s (Ishii et al., 1985; Recio-Pinto and Ishii, 1984)
when the effects of IGF-I and IGF-II on neurite outgrowth
and cell survival were described. Similar effects by insulin and
C-peptide were only described recently (Li et al., 2001, 2002b;
Pierson et al., 2002a, 2002b, 2003). Like peripheral nerve ex-
pression of NGF, the deﬁcit in IGF-I expression occurs gradu-
ally and is established at 6-week duration in the type 1 diabetic
BB/Wor-rat (Pierson et al., 2002a; Tomlinson and Fernyhough,
2000; Xu and Sima, 2001).
Clinical Studies
Circulating IGF-I activity is markedly reduced in both type
1 and type 2 diabetes (Arner et al., 1989; Ekman et al., 2000)
and does not appear to correlate with the degree of glycemic
control (Ekman et al., 2000). Crosby et al. (1992) showed
decreased IGF-I and elevated IGFBP-I levels in type 1 patients242 A. A. F. SIMA ET AL.
with peripheral neuropathy. In type 2 patients, those with clin-
ical DPN showed signiﬁcantly lower levels of IGF-I compared
todiabeticpatientswithoutDPNornondiabeticcontrolsubjects
(Guo et al., 1999). Similar results were reported by Migdalis
et al. (1995), who demonstrated decreased IGF-I plasma lev-
els as well as decreased densities of IGF-IR on red blood
cellsintype 2patientswithsensoryandautonomicneuropathy,
compared to non-neuropathic patients and nondiabetic control
subject. These ﬁndings suggest an association between DPN
and impaired IGF-I activity. Of the other IGFs, insulin and
C-peptide are certainly deﬁcient in type 1 diabetes, whereas
they may be increased systemically, at least in early insulin
resistant type 2 diabetes. As to whether the peripheral insulin
resistanceoftype2diabetesalsoappliestotheperipheraland/or
central nervous system is not known. These differences in the
availability of IGFs, including insulin and C-peptide, are likely
to account for some of the neurotrophic deprivations seen in
type 1 diabetes and may relate to the generally more severe
manifestations of DPN in type 1 diabetes (Sima and Sugimoto,
1999; Sugimoto et al., 2000a).
Experimental Studies
Neurotrophic factor activities in peripheral nerve tissues
have been studied in both type 1 and type 2 diabetic animal
modes. In both the STZ and BB/Wor rats, there is a progressive
reductioninNGFmRNAandotherneurotrophinswithduration
ofdiabetes(Fernyhoughetal.,1994,1998;Piersonetal.,2002a,
2002b;RiazandTomlinson,1996;TomlinsonandFernyhough,
2000; Xu and Sima, 2001). Circulating levels of serum IGF-I
are diminished (Bornfeldt et al., 1989; Sima et al., 1997b). In
contrast, in type 2 animal models such as the ZDF(fa/fa) rat
and the BB/Z rat (Sima et al., 1997a), IGF-I expression is not
reducedinperipheralnerveorspinalcord(Piersonetal.,2002a,
2002b, 2003; Wuarin et al., 1994, 1996; Zhuang et al., 1997),
whereas IGF-II gene expression is reduced in peripheral nerve
of the ZDF(fa/fa) rat. Likewise, the expression of IGF-I and
its receptor is signiﬁcantly down-regulated in DRG and the su-
perior cervical ganglion in type 1 animal models (Bitar et al.,
1997;Craneretal.,2002;IshiiandLupien,1995;Piersonetal.,
2003; Wuarin et al., 1994; Xu et al., 2002), but not in the type 2
BB/Z rat (Pierson et al., 2003). Because IGFs regulate the gene
expression of neuroskeletal proteins such as tubulin and neu-
roﬁlaments, which in turn are determinants for axonal caliber,
these discrepancies between their expression in type 1 and type
2 animal models may account for the substantially milder ax-
onal atrophy seen in the latter (Murakawa et al., 2002; Sima
et al., 2000; Yagihashi et al., 1994) (Figure 3). This notion is
supported by experiments demonstrating that infusion of either
IGF-I or IGF-II into crushed sciatic nerves increases the dis-
tance of motor and sensory axon degeneration (Glazner et al.,
FIGURE 3
Protein expression of IGF-IR in dorsal root ganglia from
type 1 diabetic BB/Wor and type 2 diabetic BB/Z rats at
various time points after sciatic nerve crush injury (A). At
baseline time point 0 in uninjured 6-week diabetic rats, the
IGF-IR expression was signiﬁcantly (P <.001) up-regulated
in type 1 rats but not in type 2. Following crush-injury, type 2
diabetic rats showed an immediate upregulation of IGF-IR not
signiﬁcantly different from that of age-matched control
animals, whereas the expression in type 1 rats showed an
undulating and suppressed proﬁle. Two-way ANOVA showed
P <.001 (F = 303) for time and P <. 001 (F = 60) for
Group × Time. This corresponded to a markedly suppressed
expression of β-tubulin in type 1 diabetic rats (B), which from
24 hours post crush injury was signiﬁcantly (P <. 001) lower
than in both control and type 2 BB/Z rats. Instead,
isohyperglycemic and normoinsulinemic type 2 rats showed a
normal up-regulation of β-tubulin. Reproduced with
permission from Journal of Neuropathology and
Experimental Neurology.IGF AND NEUROLOGICAL COMPLICATIONS 243
1993; Kanje et al., 1989). However, other ligands of the IGF
family, such as insulin itself, as well as C-peptide, may in part
account for these differences in the expression of neuroskeletal
proteins. Insulin has neurotrophic effects on peripheral nerve
by stabilizing neuroﬁlament and tubulin gene expression in a
dose-dependent manner (Fernyhough et al., 1993; Wang et al.,
1992), and is required for NGF to exert its protective effects
on human neuroblastoma cells (Recio-Pinto and Ishii, 1984).
Similar effects have been demonstrated for C-peptide (Li et al.,
2001; Pierson et al., 2003; Sima et al., 2002), and are probably
mediated via C-peptide’s insulinomimetic effects (Grunberger
et al., 2001).
A preserved integrity of the IGF system is a requirement for
normal nerve regeneration (Chiarelli et al., 2000; Ishii, 1995;
Pu et al., 1999; Stoll and Muller, 1999; Xu and Sima, 2001).
Nerve ﬁber regeneration is a spatiotemporally regulated multi-
step process and a complex interplay between Schwann cells,
macrophages,ﬁbroblasts,andneuronalelements(XuandSima,
2001). Nerve damage induces early gene responses, which in-
clude the ﬁrst wave of neurotrophic factors by Schwann cells,
followed by macrophage recruitment and Wallerian degenera-
tion, interleukin induction, Schwann cell proliferation, and the
second wave of neurotrophic factor production (Xu and Sima,
2001). This cascade of interdependent events foster the synthe-
sis of neuronal cytoskeletal elements that initiate and sustain
axonal regrowth and regenerations. The early gene responses
oftrophicfactorsincludethesequentialup-regulationofIGF-I,
c-fos, and NGF. In type 1 insulinopenic BB/Wor rat, this se-
quence of events is markedly delayed and suppressed in its
magnitude (Pierson et al., 2002b; Xu and Sima, 2001), follow-
ing sciatic nerve crush injury (Figure 3). These abnormalities
are subsequently associated with perturbed expression of neu-
roﬁlaments and tubulins and impaired ﬁber regeneration. Inter-
estingly in the normoinsulinemic but isohyperglycemic type 2
BB/Z rat, these abnormalities do not occur or are substantially
milder (Pierson et al., 2002b) and are prevented in the type 1
model following C-peptide replacement (Pierson et al., 2003),
followed by normalization of neuroskeletal protein expression
(Figure 4). These ﬁndings suggest that the perturbed regen-
eration in type 1 diabetes is not likely to be the result of
hyperglycemia per se, but rather the consequence of insulin
and/or C-peptide deﬁciency. This construct is also reﬂected by
a close to normal nerve regeneration in the type 2 model and in
C-peptide–replaced type 1 rats, the latter most likely medi-
atedbyC-peptide’sinsulin-enhancingeffect(Grunbergeretal.,
2001).
FurthereffectsofC-peptidereplacementincludenormaliza-
tionoftheexpressionofIGF-I,IGF-IR,andtheIRinperipheral
nerve of type 1 BB/Wor rat (Sima et al., 2001a), which may be
mediated via its effect on NF-κB (Zhang et al., 2002).
One of the most profound differences between DPN in both
human and experimental type 1 and type 2 DPN is the progres-
sivenodalandparanodalchangesoccurringintheformer(Sima
et al., 1988; Sugimoto et al., 2000a). These changes consist of
disruption of the paranodal barrier (axo-glial dysjunction) and
migration of crucial sodium channels away from the nodal gap
(Cherian et al., 1996; Sima et al., 1986, 1988), and account for
the more severe nerve conduction defect in type 1 DPN.
Interestingly, the insulinomimetic C-peptide prevents these
changesintype2BB/Worrats(Simaetal.,2000,2001b),which
we have suggested may be accounted for by the colocalization
of the IR to axo-glial junctions of the paranodal apparatus and
the nodal axolemma (Sugimoto et al., 2000b, 2002). Prelimi-
nary studies in our laboratory have shown that the expression
or post-translational modiﬁcations of several key molecules of
theparanodalapparatus,suchascaspr,contactin,ankyrinG,and
sodium channel β subunits of the nodal axolemma, are signiﬁ-
cantly perturbed in type 1 BB/Wor rats but not in type 2 BB/Z
rats, and that these abnormalities can be largely prevented by
C-peptide (Sima et al., 2001b, unpublished data). These data
strongly suggest that deﬁciencies of insulin itself and its
“helper” C-peptide play important roles in the pathogenesis
of type 1 DPN and are likely to be involved in the downstream
gene regulation of several members of the IGF system, and that
C-peptide replacement in this type of diabetes mellitus may
provide a signiﬁcant therapeutic potential in type 1 DPN.
In Vitro Studies
The effects of IGF on diabetic neuropathy have been stud-
ies in vitro in cultured superior cervical ganglia (SCG) and
DRG neurons, Schwann cells, and neuroblastoma SH-SY5Y
cells exposed to high concentrations of glucose or mannitol.
High glucose inhibits neurite outgrowth and initiates apoptosis
via activation of caspase-3 in cultured SCG and DRG neurons.
The addition of IGF-I ameliorates these changes and prevents
activation of caspase-3 and neuronal apoptosis (Russell et al.,
1999). Similarly, Schwann cells cultured in high glucose un-
dergo apoptosis, which is prevented by IGF-I via PI 3-kinase
activation (Delaney et al., 2001).
The neuroblastoma SH-SY5Y cell system is a well-
characterizedinvitromodelforstudyingneuronaldevelopment
and apoptosis. Numerous studies have demonstrated that high
glucose/mannitol–induced apoptosis of SH-SY5Y cells can be
rescued by IGF-I (Cheng and Feldman, 1998; Matthews and
Feldman, 1996; Singleton et al., 1996; van Golen et al., 2000;
van Golen and Feldman, 2000). Recently, we demonstrated
that glucose-induced apoptosis in SH-SY5Y cells is dose and
time dependent. To separate the effect of glucose toxicity from
that of hyperosmolarity, we also examined the effects of the
same concentrations of mannitol on SH-SY5Y cell apoptosis.244 A. A. F. SIMA ET AL.
FIGURE 4
Protein expression of IGF-IR in dorsal root ganglia in type 1 diabetic BB/Wor rat and those replaced with C-peptide (A).
C-peptide replacement from onset of diabetes (75 nmol/kg body weight/day) resulted in a normalization of the IGF-IR expression
following sciatic nerve crush injury induced at 6 weeks of diabetes. This was accompanied by a normal expression proﬁle of β-III
tubulin (B), demonstrating that C-peptide has beneﬁcial and normalizing effects on cytoskeletal protein expression in
regenerating sensory nerve ﬁbers in type 1 diabetes.IGF AND NEUROLOGICAL COMPLICATIONS 245
The extent of apoptosis induced by mannitol was signiﬁcantly
less than that induced by same concentration of glucose (ex-
cept for extremely high concentration), suggesting that glu-
cose toxicity per se is additive to the hyperosmolar apoptotic
effects.
Our data showed that insulin (4 nM) signiﬁcantly in-
creased neurite outgrowth of SH-SY5Y cells and decreased
apoptosis under high glucose concentrations. The addition of
C-peptidetoinsulinshowedfurthersigniﬁcantincreasesinneu-
riteoutgrowthandpreventionofapoptosis.Thecombinationof
C-peptide and insulin enhanced phosphorylation of IR, but not
IGF-IR, suggesting that insulin and C-peptide may signal via a
commonpathway.Ontheotherhand,IGF-Ishowedthegreatest
effectonneuriteoutgrowth;however,thecombinationofIGF-I
and C-peptide did not result in an additive effect on neurite
outgrowth (Zhang et al., 2001, 2002).
Insummary,itiswellestablishedthatabnormalitiesofIGFs
play central roles in the pathogenesis of DPN and that they
impair axonal integrity and nerve ﬁber regeneration in DPN.
These effects appear to be most expressed in type 1 diabetes,
suggesting that factors other than hyperglycemia are at play.
Data from our laboratory, using the proinsulin C-peptide as an
insulinomimeticum,stronglysuggestthatinsulindeﬁciencyper
se may be the major underlying culprit in the various perturba-
tions of the IGF system. We therefore suggest that C-peptide,
like insulin, be incorporated as one of the key ligands in the
IGF system.
TheclinicalusageofIGF-Iasatherapeuticagentisprobably
associatedwithseveralproblemssuchasrouteofadministration
and its ubiquitous effects with potential adverse effects. Never-
theless, there are some short-term beneﬁcial effects reported in
both type 1 and type 2 patients with recombinant human IGF-I
(Thrailkill, 2000). However, long-term efﬁcacy data are lack-
ing. Probably, a more applicable and safer approach would be
to secondarily modify and correct the IGF system, particularly
in type 1 diabetes, via replacement of C-peptide for instance
(Sima et al., 2001b).
CNS COMPLICATION
Recent studies have provided substantial evidence that dia-
beteshasuniqueimpactsontheCNS.Diabetesincreasesstroke
risk,affectsglucosetransport,andalterstheblood-brainbarrier
(McCall, 1992; Mooradian, 1997). Studies in clinical and ex-
perimental diabetes suggest a variety of abnormalities in brain
structure, neurotransmitters, and electrophysiology (Dejgaard
etal.,1991;Jakobsenetal.,1987;Kamijoetal.,1993;Lackovic
etal.,1990;Luse,1970;Salkovicetal.,1995;Simaetal.,1992;
Welsh and Wecker, 1991). The incidence of psychiatric dis-
orders are more common in diabetic patients compared with
age-matched nondiabetic subjects (Popkin, 1997), such as ma-
jor depression and phobias (Pozzessere et al., 1988). Cogni-
tive deﬁcits have been documented in diabetic patients, includ-
ing memory retention/retrieval and complex reasoning skills
(Gispen and Biessels, 2000; Helkala et al., 1995; Mooradian
et al., 1988; Popkin et al., 1988; Pozzessere et al., 1988, 1991).
The reasons for this may be multifold, such as a higher in-
cidence of stroke, which also behaves differently in diabetic
patients (“stroke in evolution”) (Asplund et al., 1980; Fisher
and Garcia, 1996; Raev, 1993; Weinberger et al., 1983), ar-
teriolosclerosis with cortical microinfarctions (Dolman, 1963;
Reske-Nielsen et al., 1965), and/or diffuse white matter lesions
(“leucoariosis”) (Pantoni and Garcia, 1997). These changes are
more common in elderly type 2 patients and are accentuated by
hypertension. In contrast, repeated episodes of hypoglycemia
in type 1 patients are known to cause neuronal loss in the hip-
pocampus, cortical layers 3 and 5, and cerebellar Purkinje cells
(Agardh et al., 1981; Auer et al., 1984a, 1984b), with ensu-
ing cognitive and neurological deﬁcits. However, Kramer et al.
(1998) and Schoenle et al. (2002) reported that type 1 diabetic
patients show a duration-dependent decline in cognitive func-
tion, which is unrelated to hypoglycemic episodes. Therefore,
cognitive deﬁciency may be caused by diabetes per se. Taken
together, mounting evidence support the notion that the brain is
not spared from the complications of diabetes. In diabetic rats,
reductionofneocorticalthicknessassociatedwithneuronalloss
(Jakobsen et al., 1987; Luse, 1970), decreased acetylcholine
synthesis and release (Welsh and Wecker, 1991), impaired spa-
tial memory and learning (Biessels et al., 1996; Popovic et al.,
2001), and altered synaptic integrity of the hippocampus as re-
ﬂected by long-term potentiation deﬁcits (Biessels et al., 1998;
Kamal et al., 2000) have been demonstrated. These animal
studies also suggest that a primary encephalopathy occurs in
diabetes.
The mechanisms by which diabetes causes CNS complica-
tionsarenotclear.Hippocampusandfrontalcortexareessential
parts of the limbic system and are intimately correlated with
higher cognitive functions. They are vulnerable parts of the
brain, with high susceptibility to ischemia and hypoglycemia.
In CNS, apoptotic neuronal cell death has been described in
ischemic brain injury (Kihara et al., 1994; Li et al., 1995;
Linnik et al., 1993; Nitatori et al., 1995) and in neurodegen-
erative diseases, such as Alzheimer disease, Parkinson’s dis-
ease, Huntington’s disease, and amyotrophic lateral sclerosis
(Hartleyetal.,1994;Looetal.,1993;Offenetal.,1999;Stefanis
et al., 1997; Tatton et al., 1997, 1998; Ziv and Melamed, 1998).
We recently reported on a duration-dependent neuronal apop-
tosis in hippocampus of type 1 diabetic BB/Wor rats, which
is accompanied with neuronal loss and cognitive impairments.
As shown in Figure 5, perturbations of the IGF system was246 A. A. F. SIMA ET AL.
FIGURE 5
Perturbations of the IGF system in CNS in type 1 diabetic BB/Wor-rat. (A) Northern blot hybridization (representative of three
blots). The mRNA levels of and IGF-I, IGF-II, IGF-IR, and IR were signiﬁcantly reduced in hippocampi of 2-month diabetic
BB/Wor rats compared to age-matched control rats (B). Control values are arbitrarily set to 100. Position of 28s ribosome is
indicated. Arrows indicate the mRNA bands of IGF-I (7.5 kb), IGF-II (3.8 kb), IGF-IR (11 kb), and IR (11 kb) in (A). The
GAPDH bands of the corresponding gel show that equal amounts of RNA was loaded onto each lane. C, control; D, diabetic.
∗P <. 001 versus control. Reproduced with permission from Brain Research.
demonstrated prior to the development of hippocampal apop-
tosis in the BB/Wor rat (Li et al., 2002a). These data suggest
that neuronal apoptosis in the diabetic animals is likely to con-
tribute to the cognitive deﬁciencies observed in type 1 diabetic
patients. It is of interest to note that in Alzheimer disease, both
IR and IGF-IR are signiﬁcantly down-regulated in hippocam-
pus (Terry et al., 2001).
IGF and the CNS Complications of Diabetes
in Experimental Animals
Ishii (1995) initially proposed that decreased IGF activities
may contribute to CNS alterations in diabetes. This hypothe-
sis has subsequently been supported by a series of clinical and
experimental studies. Many studies show that IGF activity is
impaired in the CNS of experimental diabetic animals. The ex-
pression of IGF-I and IGF-II are reduced in the spinal cord
and brain of type 1 diabetic STZ and BB/Wor rats (Busiguina
et al., 1996; Wuarin et al., 1994; Zhuang et al., 1997; Li et al.,
2002a, 2002b) and in the spontaneously diabetic ZDF(fa/fa)
(Wuarin et al., 1996). Diminished IGF-II gene expression in
the brain precedes abnormalities in brain structure, neurotrans-
mitter levels, Na+,K+-ATPase activity and learning behaviors
in STZ-induced diabetes (Wuarin et al., 1996), suggesting that
alterations of the IGF system exerts an important role in theIGF AND NEUROLOGICAL COMPLICATIONS 247
pathogenesis of CNS complications. We have used a model
of type 1 diabetes, the spontaneous type 1 diabetic BB/Wor
rat, to examined CNS alterations of the IGF system. In this
model, IGF-I, IGF-II, IGF-IR, and IR expression was exam-
ined in 2- and 8-month diabetic animals, representing an early
and a chronic state of diabetes. In both 2-month and 8-month
diabetic animals, the expression of IGF-I and IGF-II, IGF-IR,
and IR were signiﬁcantly reduced compared to age-matched
control rats, suggesting that the IGF system is impaired at the
earlystageandcontinuetodeclinewiththediseaseprogression
(Lietal.,2002a).TheearlyimpairmentsoftheIGFsystempre-
ceded signiﬁcant apoptosis and neuronal cell loss in the CA1
region of the hippocampus, which became evident only at 8-
month duration of diabetes. Apoptotic activity correlated with
deoxylnucleotidyl transferase-mediated dUTP nick-end label-
ing (TUNEL) staining, DNA laddering, caspase-3 activity, and
Bax/Bclx expression. Spatial learning and memory were sig-
niﬁcantly impaired in diabetic animals (Li et al., 2002a). These
results indicate a duration-dependent IGF-associated neu-
ronal apoptosis leading to cognitive dysfunction. Interestingly,
C-peptide replacement corrected partially but signiﬁcantly the
abnormalities in IGF-I, IGF-II, IGF-IR, and IR expression in
the hippocampus and partially prevented hippocampal apopto-
sis, neuronal loss, and the functional cognitive impairment (Li
et al., 2002b).
In STZ-diabetic rats, insulin treatment prevents water
maze learning and hippocampal impairments of long-term
potentiation (Biessels et al., 1998), and reverses the prolonged
latencies of auditory and visual evoked potentials (Biessels,
1999). These results suggest that insulin deﬁciency may play
a crucial role in impaired CNS function in type 1 diabetes.
Because insulin replacement therapy partially restores IGF-II
mRNA levels in the cerebral cortex and spinal cord in the same
animal model (Wuarin et al., 1996), insulin may exert its role
via activation of the IGF system, which would be consistent
with the same effects of the insulinomimetic C-peptide.
In Vitro Studies
Incerebrocorticalandcerebellargranulecellcultures,IGF-I
signiﬁcantly reduces cell death induced by glucose deprivation
(Harper et al., 1996). Two IGF analogues: QAYL and B-chain
mutants, which show reduced afﬁnity for IGFBPs, are as effec-
tiveasIGF-Iinpromotingcellsurvivalinconditionsofglucose
deprivation, indicating that IGF-I promotes neuronal survival.
Apoptosis of cerebellar granule cells is blocked by IGF-I (Galli
et al., 1995). Preliminary data from our laboratory suggest that
primary hippocampal neurons grown in high glucose are pro-
tected from apoptosis by either IGF-I, insulin, or C-peptide (Li
et al., unpublished data).
DIFFERENCE IN IGF ACTIVITIES IN THE CNS
AND PERIPHERAL NERVE SYSTEM (PNS)
The alterations in IGF activities differ in peripheral nerve
from those in the central nervous system in both STZ-diabetic
rats and BB/Wor rats. The neurophysiological abnormalities of
peripheral nerve usually occur more rapidly than those of the
central nervous system (Biessels, 1999; Kamijo et al., 1993; Li
et al., 2002b; Sima et al., 1992).
ThepatternsofdeclineintheIGFsystemisdifferentinPNS
and CNS in type 1 diabetic BB/Wor rats. IGF perturbations are
established in peripheral nerves at 6-week duration of diabetes,
whereas this is only evident at 2-month duration of diabetes in
thehippocampus.Furthermore,inCNSofdiabeticBB/Worrats,
IGF-I, IGF-II, IGF-IR, and IR are decreased at both the mRNA
and protein levels (Li et al., 2002a), whereas in the peripheral
nerve of the same model, IGF-I and IGF-II expression is re-
duced, but IR and IGF-IR expression are increased (Sugimoto
et al., 2000b; Xu and Sima, 2001). These data suggest that in-
sulin deﬁciency may involve different mechanisms by which
the IGF system is regulated in the PNS versus the CNS.
CONCLUSIONS AND
FUTURE DEVELOPMENTS
Morethan15yearsoffairlyextensiveexperimentalresearch
and limited clinical research have established the IGF system
and its perturbations as important pathogenetic factors in
the development of the neurological complications, particu-
larly those associated with type 1 diabetes. There is strong
evidence to suggest that abnormalities in IGF metabolism
occur independently of hyperglycemia and that they are linked
to insulinopenia. Limited clinical trials have indicated that
restoration of IGF activities may prevent or even to some
extent reverse neurological deﬁcits associated with diabetes.
However, the ubiquity of IGF activities poses a challenge to
target speciﬁc tissues, even within the nervous system, because
the perturbations of various gene responses of IGFs in the CNS
and the PNS divert in opposite directions.
There is evidence to suggest that insulin and the proinsulin
C-peptide play important roles in regulating and correcting
the diverse aberrations of IGFs. Hence, a logical conjecture of
these relationships would be to replenish the insulinomimetic
C-peptideinparalleltooptimalinsulintreatment.Infactseveral
short-term clinical trials have underlined the beneﬁcial effects
of C-peptide on several chronic complications, which are in
keeping with the experimental data. However, a major obstacle
and challenge is to ﬁnd support for large scale Food and Drug
Administration (FDA)-approved clinical trials testing the efﬁ-
cacy of C-peptide in diabetic complications. Because patents
on C-peptide are long expired, the incentives on part of the248 A. A. F. SIMA ET AL.
industry to provide the peptide and funds for necessary trials
are nonexisting. This stumbling block needs to be overcome by
National Institutes of Health (NIH) mechanisms or by support
from nonproﬁt organizations to initiate appropriately designed
clinical trials. A potential but distant possibility is the develop-
mentswithinthehumangenomeresearchprojectstargetingnot
only IGF-I itself, but also related peptides such as C-peptide or
others.However,thesepossibilitiesaretothebestoftheknowl-
edge not yet in the plans.
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